Search Results - "Tye, S. J."

Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders by Frye, M A, Nassan, M, Jenkins, G D, Kung, S, Veldic, M, Palmer, B A, Feeder, S E, Tye, S J, Choi, D S, Biernacka, J M

“…The objective of this study was to determine whether proteomic profiling in serum samples can be utilized in identifying and differentiating mood disorders. A…”
Get full text

Nucleus accumbens deep-brain stimulation efficacy in ACTH-pretreated rats: alterations in mitochondrial function relate to antidepressant-like effects by Kim, Y, McGee, S, Czeczor, J K, Walker, A J, Kale, R P, Kouzani, A Z, Walder, K, Berk, M, Tye, S J

“…Mitochondrial dysfunction has a critical role in the pathophysiology of mood disorders and treatment response. To investigate this, we established an animal…”
Get full text

Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass by Davis, J, Maes, M, Andreazza, A, McGrath, J J, Tye, S J, Berk, M

“…There is currently considerable imprecision in the nosology of biomarkers used in the study of neuropsychiatric disease. The neuropsychiatric field lags behind…”
Get full text

Unified selective sorting approach to analyse multi-electrode extracellular data by Veerabhadrappa, R., Lim, C. P., Nguyen, T. T., Berk, M., Tye, S. J., Monaghan, P., Nahavandi, S., Bhatti, A.

“…Extracellular data analysis has become a quintessential method for understanding the neurophysiological responses to stimuli. This demands stringent techniques…”
Get full text

Ventral tegmental ionotropic glutamate receptor stimulation of nucleus accumbens tonic dopamine efflux blunts hindbrain-evoked phasic neurotransmission: Implications for dopamine dysregulation disorders by Tye, S.J, Miller, A.D, Blaha, C.D

“…Highlights • Midbrain iGluR activation potentiates basal nucleus accumbens dopamine efflux. • Midbrain iGluR activation attenuates hindbrain-evoked transient…”
Get full text

Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys by RUPNIAK, N. M. J, TYE, S. J, FIELD, M. J

“…Hepatotoxicity limits the clinical utility of the cholinesterase inhibitor tacrine as a palliative therapy for Alzheimer's disease. The present studies…”
Get full text

Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates by Rupniak, N M, Tye, S J, Brazell, C, Heald, A, Iversen, S D, Pagella, P G

“…Cholinergic replacement therapy for Alzheimer's disease using existing cholinesterase inhibitors is compromised by short duration, meagre benefits restricted…”
Get more information

Evidence against a specific effect of cholinergic drugs on spatial memory in primates by Rupniak, N M, Samson, N A, Tye, S J, Field, M J, Iversen, S D

“…A scopolamine-like delay-dependent impairment in spatial delayed response performance in rhesus monkeys was induced by irrelevant interpolated activity or by…”
Get more information

Comparison of the effects of selective and nonselective muscarinic agonists on cognition and thermoregulation in primates by Rupniak, N M, Tye, S J, Iversen, S D

“…Peripheral toxicity may explain the disappointing therapeutic effects of nonselective muscarinic agonists in Alzheimer's disease. Partial agonists might…”
Get more information

Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys by RUPNIAK, N. M. J, TYE, S. J, JENNINGS, C. A, LOPER, A. E, BONDI, J. V, HICHENS, M, HAND, E, IVERSEN, S. D, STAHL, S. M

“…We examined the ability of the antiparkinsonian agent (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) to enter the systemic circulation in therapeutic…”
Get full text

Failure of d-cycloserine to reverse cognitive disruption induced by scopolamine or phencyclidine in primates by Rupniak, N M, Duchnowski, M, Tye, S J, Cook, G, Iversen, S D

“…The partial glycine agonist d-cycloserine may be of therapeutic use as a cognitive enhancer. We examined the ability of d-cycloserine (3-14 mg/kg i.m.) to…”
Get more information

Spontaneous orofacial dyskinesias in a captive cynomolgus monkey: implications for tardive dyskinesia by Rupniak, N M, Tye, S J, Steventon, M J, Boyce, S, Iversen, S D

“…We describe a syndrome of spontaneous orofacial dyskinesias and cage stereotypies in a singly housed adult cynomolgus monkey never previously exposed to…”
Get more information

NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys by Tye, S J, Rupniak, N M, Naruse, T, Miyaji, M, Iversen, S D

“…Prodrugs may be used to improve the absorption and bioavailability of certain active compounds. We have examined the ability of a novel catechol monoester of…”
Get more information

Hierarchical estimation of neural activity through explicit identification of temporally synchronous spikes by Veerabhadrappa, R., Bhatti, A., Berk, Michael, Tye, S.J., Nahavandi, S.

“…Extracellular recording from living neurons employing microelectrode arrays has attracted paramount attention in recent years as a way to investigate the…”
Get full text

Drug-induced purposeless chewing: animal model of dyskinesia or nausea? by Rupniak, N M, Tye, S J, Iversen, S D

“…Drug-induced purposeless chewing movements in rodents are often considered to represent movement disorders or dyskinesias. We have compared the ability of…”
Get full text

Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition by Uslaner, Jason M, Tye, Spencer J, Eddins, Donnie M, Wang, Xiaohai, Fox, Steven V, Savitz, Alan T, Binns, Jacquelyn, Cannon, Christopher E, Garson, Susan L, Yao, Lihang, Hodgson, Robert, Stevens, Joanne, Bowlby, Mark R, Tannenbaum, Pamela L, Brunner, Joseph, Mcdonald, Terrence P, Gotter, Anthony L, Kuduk, Scott D, Coleman, Paul J, Winrow, Christopher J, Renger, John J

“…Current treatments for insomnia, such as zolpidem (Ambien) and eszopiclone (Lunesta), are γ-aminobutyric acid type A (GABAA)-positive allosteric modulators…”
Get more information

Therapeutic efficacy of a novel transdermal delivery system for (+)-PHNO in parkinsonian squirrel monkeys by Rupniak, N M, Tye, S J, Jennings, C A, Loper, A E, Bondi, J V, Hichens, M, Iversen, S D, Stahl, S M

Get full text

VENTRAL TEGMENTAL IONOTROPIC GLUTAMATE RECEPTOR STIMULATION OF NUCLEUS ACCUMBENS TONIC DOPAMINE EFFLUX BLUNTS HINDBRAIN-EVOKED PHASIC NEUROTRANSMISSION: IMPLICATIONS FOR DOPAMINE DYSREGULATION DISORDERS by TYE, S. J, MILLER, A. D, BLAHA, C. D

Get full text

Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression by Price, J. Blair, Bronars, Carrie, Erhardt, Sophie, Cullen, Kathyrn R., Schwieler, Lilly, Berk, Michael, Walder, Ken, McGee, Sean L., Frye, Mark A., Tye, Susannah J.

“…•Synaptic plasticity modulation is central to antidepressant relief strategies.•Disruptions of bioenergetic signaling directly impact synaptic…”
Get full text

Blockade of CCK-B receptors by L-365,260 induces analgesia in the squirrel monkey by O'Neill, M F, Dourish, C T, Tye, S J, Iversen, S D

“…The potential antinociceptive effects of the selective cholecystokinin-B (CCK-B) antagonist L-365,260 were examined in the squirrel monkey tail withdrawal…”
Get more information